Recent Updates
Recently added Catalysts
ENGN Positive Sentiment

enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones

Wednesday, November 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: enGene Therapeutics appointed Erik T. Goluboff as CMO and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026. These hires support upcoming regulatory and commercial milestones for the company. The appointments coincide with the ongoing LEGEND Phase 2 trial for its lead candidate, detalimogene voraplasmid.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of experienced executives strengthens leadership.
  • Focus on upcoming regulatory and commercial milestones.
  • Ongoing LEGEND Phase 2 trial shows commitment to development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
4.1%
average across 2 past catalysts
Cash runway
~40 mo
Low dilution risk
Lead asset
EG-70
Phase 2 · Superficial Bladder Cancer

Full Press Release Details

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026. enGene's lead investigational candidate, detalimogene voraplasmid (detalimogene) is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes

Frequently Asked Questions

Who were the new executives appointed at enGene?

Erik T. Goluboff was appointed as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer.

When do the new appointments at enGene take effect?

The appointments are effective November 9, 2026.

What is enGene's lead investigational candidate?

enGene's lead candidate is detalimogene voraplasmid.

What trial is detalimogene voraplasmid currently in?

It is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial.

ShareAdd on Google
Tags: ENGN enGene detalimogene voraplasmid LEGEND Phase 2 executive appointments regulatory milestones
Last updated: Nov 11, 2026

Biotech snapshot

Cash runway
$266M liquidity · $6M/mo burn
~40 mo
Low dilution risk
Lead asset
EG-70Phase 2
Superficial Bladder Cancer →

Catalyst track record

+23%
best trade around ENGN's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ENGN.

See every catalyst's timing & PoA →